Market Cap: $13.05M
KA
Kazia Therapeutics Ltd ADR
KZIA
NASDAQUSD
Market Cap: $13.05M
Emerging Leader in Immunotherapy: Oncolytics Biotech's Innovative Approach to Cancer Treatment Oncolytics Biotech Inc. is making notable advancements in the cancer drug market, which is expected to gr…
Kazia Therapeutics Sees Positive Shift in Market Sentiment Kazia Therapeutics Ltd, a biotechnology company focused on developing innovative therapies for cancer treatment, experiences a notable declin…
Kazia Therapeutics Shifts Market Sentiment with Significant Decline in Short Interest Kazia Therapeutics Ltd, a biotechnology company focused on developing innovative therapies for cancer treatment, e…
Kazia Therapeutics Reaffirms Its Position in Cancer Innovation Kazia Therapeutics Limited, a Sydney-based clinical-stage oncology firm, has successfully regained compliance with Nasdaq listing standar…
Kazia Therapeutics Regains Compliance with Nasdaq Listing Standards, Strengthening Oncology Pipeline Kazia Therapeutics Limited, a Sydney-based clinical-stage oncology company, announces a significant…
Kazia Therapeutics Secures $50 Million to Propel Oncology Programs Kazia Therapeutics Limited has embarked on a strategic initiative to enhance its financial foundation, announcing a private placement…
Kazia Therapeutics Secures Funding to Advance Oncology Initiatives Kazia Therapeutics Limited announces a pivotal private placement aimed at raising approximately $50 million, a strategic maneuver des…
Kazia Therapeutics Advances in Brain Cancer Treatment with New Clinical Trial Initiatives Kazia Therapeutics, a prominent player in the biotechnology sector, is making significant strides in the treat…
Kazia Therapeutics Advances Innovative Cancer Treatment Kazia Therapeutics, a clinical-stage oncology company, is making significant strides in the development of its lead compound, GDC-0084, an oral…
Kazia Therapeutics Advances in Glioblastoma Treatment Kazia Therapeutics Limited is making significant strides in its mission to develop innovative cancer therapies, particularly with its lead drug ca…
Kazia Therapeutics Reports Encouraging Breakthrough in Triple-Negative Breast Cancer Treatment Kazia Therapeutics Limited, an oncology-focused drug development company, announces a significant advance…
Kazia Therapeutics Reports Breakthrough in Triple-Negative Breast Cancer Treatment Kazia Therapeutics Limited (Nasdaq: KZIA) makes headlines with a groundbreaking development in oncology, showcasing p…
Kazia Therapeutics Enhances Focus on Innovative Cancer Treatments Kazia Therapeutics announces significant advancements in its clinical pipeline, emphasizing its commitment to developing innovative th…
Kazia Therapeutics Advances in Cancer Treatment with New Drug Development Kazia Therapeutics, an innovative biotechnology firm, makes significant strides in the realm of cancer treatment through its l…
Kazia Therapeutics Advances Cancer Treatment Pipeline with Promising Drug Developments Kazia Therapeutics, an Australian oncology-focused biotechnology company, continues to make significant strides i…
Kazia Therapeutics Partners for Groundbreaking Cancer Immunotherapy Development Kazia Therapeutics Limited has recently entered an exclusive collaboration and in-licensing agreement with QIMR Berghofe…
Kazia Therapeutics Partners with QIMR Berghofer to Advance Innovative Cancer Treatment Kazia Therapeutics Limited announces a significant partnership with QIMR Berghofer, focusing on the development o…
Kazia Therapeutics Advances Cancer Immunotherapy with Innovative PD-L1 Degrader Program Kazia Therapeutics Limited announces an exclusive collaboration with QIMR Berghofer Institute to develop a groun…
Kazia Therapeutics Reports Promising Outcomes in Triple-Negative Breast Cancer Treatment Kazia Therapeutics Limited, an oncology-focused drug development company headquartered in Sydney, Australia, an…
Kazia Therapeutics Reports Promising Results in Triple-Negative Breast Cancer Treatment Kazia Therapeutics Limited, an oncology-focused drug development company based in Sydney, Australia, announces e…
Kazia Therapeutics Reports Significant Tumor Regression in Expanded Access Case for Triple-Negative Breast Cancer Kazia Therapeutics Limited, an Australian oncology-focused drug development firm, anno…
Kazia Therapeutics Advances Cancer Treatment with Promising Paxalisib Findings Kazia Therapeutics Limited, an oncology-focused drug development company, announces significant advancements in the treat…
Kazia Therapeutics Expands Paxalisib's Potential in HER2-Positive Metastatic Breast Cancer Kazia Therapeutics Limited announces groundbreaking findings from a collaborative study led by Professor Sudh…
Kazia Therapeutics Expands Therapeutic Potential of Paxalisib in HER2-Positive Breast Cancer Kazia Therapeutics Limited, an oncology-focused drug development company, recently unveils promising data f…
Kazia Therapeutics Advances Cancer Treatment with Innovative Trial Kazia Therapeutics (KZIA) is making significant strides in cancer therapy through its recently announced preliminary results from a P…